Diabetes drug metformin tested as potential ALS treatment
NCT ID NCT04220021
First seen Dec 08, 2025 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study tests whether metformin, a common diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Researchers will also check if it lowers toxic proteins linked to the disease. About 41 participants will take metformin for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UF Health at the University of Florida
Gainesville, Florida, 32610, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin
What this could lead to
If successful, this could point toward a treatment that slows progression of C9orf72 ALS by reducing harmful proteins.
What could go wrong
This is a small, early-phase trial focused on safety, not effectiveness. Metformin may not affect the disease course, and results may not apply to all ALS patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.